Genprex (GNPX) Competitors $0.22 +0.00 (+0.64%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.23 +0.00 (+2.08%) As of 08:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. OKUR, GBIO, CLNN, FGEN, MIRA, RNTX, TPST, PMN, SCYX, and CINGShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include OnKure Therapeutics (OKUR), Generation Bio (GBIO), Clene (CLNN), FibroGen (FGEN), MIRA Pharmaceuticals (MIRA), Rein Therapeutics (RNTX), Tempest Therapeutics (TPST), Promis Neurosciences (PMN), SCYNEXIS (SCYX), and Cingulate (CING). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Its Competitors OnKure Therapeutics Generation Bio Clene FibroGen MIRA Pharmaceuticals Rein Therapeutics Tempest Therapeutics Promis Neurosciences SCYNEXIS Cingulate OnKure Therapeutics (NASDAQ:OKUR) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends. Do analysts rate OKUR or GNPX? OnKure Therapeutics currently has a consensus target price of $32.33, suggesting a potential upside of 1,508.62%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Genprex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Genprex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is OKUR or GNPX more profitable? OnKure Therapeutics' return on equity of -49.13% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets OnKure TherapeuticsN/A -49.13% -45.72% Genprex N/A -664.65%-370.18% Which has better valuation and earnings, OKUR or GNPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnKure TherapeuticsN/AN/A-$52.67M-$5.26-0.38GenprexN/AN/A-$21.11MN/AN/A Which has more risk & volatility, OKUR or GNPX? OnKure Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Genprex has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500. Do institutionals & insiders hold more shares of OKUR or GNPX? 91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by company insiders. Comparatively, 0.4% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor OKUR or GNPX? In the previous week, Genprex had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for Genprex and 0 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score. Company Overall Sentiment OnKure Therapeutics Neutral Genprex Neutral SummaryOnKure Therapeutics beats Genprex on 9 of the 11 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.29M$2.98B$5.48B$9.56BDividend YieldN/A2.46%3.99%4.17%P/E RatioN/A17.9729.9325.14Price / SalesN/A179.55375.2276.13Price / CashN/A41.8335.9458.58Price / Book1.487.238.105.59Net Income-$21.11M-$54.43M$3.26B$265.48M7 Day Performance-4.16%0.22%0.68%1.22%1 Month Performance-17.39%5.59%2.45%0.39%1 Year Performance-84.41%9.98%27.72%23.47% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex1.3223 of 5 stars$0.22+0.6%N/A-85.1%$7.29MN/A0.0020OKUROnKure Therapeutics2.3888 of 5 stars$2.21-3.1%$32.33+1,363.0%N/A$30.80MN/A-0.42N/APositive NewsUpcoming EarningsGBIOGeneration Bio3.5668 of 5 stars$4.44-1.6%$80.00+1,701.8%-81.3%$30.23M$24.56M-0.41150CLNNClene3.0489 of 5 stars$3.54+1.4%$40.00+1,029.9%-18.4%$28.85M$340K-0.88100FGENFibroGen4.4301 of 5 stars$6.92-1.6%$250.00+3,512.7%-31.0%$28.41M$29.62M-2.77570News CoverageAnalyst ForecastMIRAMIRA Pharmaceuticals2.2336 of 5 stars$1.65-1.2%$14.00+748.5%-35.7%$28.26MN/A-3.242Upcoming EarningsRNTXRein TherapeuticsN/A$1.17-8.3%N/AN/A$28.14MN/A-0.419News CoverageHigh Trading VolumeTPSTTempest Therapeutics2.1572 of 5 stars$7.23-4.1%$30.00+314.9%-61.4%$27.77MN/A-0.4020Negative NewsUpcoming EarningsPMNPromis Neurosciences2.0296 of 5 stars$0.77-8.7%$4.33+462.0%-60.4%$27.61MN/A-15.425News CoverageUpcoming EarningsSCYXSCYNEXIS0.5618 of 5 stars$0.69-1.4%N/A-53.0%$27.31M$3.75M-1.2360Upcoming EarningsGap UpCINGCingulate2.3236 of 5 stars$5.18-0.2%$26.00+401.9%+1,452.9%$26.71MN/A-0.6120Upcoming EarningsGap Up Related Companies and Tools Related Companies OKUR Competitors GBIO Competitors CLNN Competitors FGEN Competitors MIRA Competitors RNTX Competitors TPST Competitors PMN Competitors SCYX Competitors CING Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
